New combo therapy aims to shrink kidney tumors before surgery
NCT ID NCT02210117
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether giving immunotherapy drugs (nivolumab alone or with bevacizumab or ipilimumab) before surgery is safe for people with advanced kidney cancer that has spread. About 104 participants will receive one of these treatments before their tumor is removed. The main goal is to check for side effects, and researchers will also look at how the drugs change the immune system in the blood and tumor tissue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rewrite the genetic story of resistant kidney cancer?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome